GRTS vs. IPSC, JSPR, MOLN, OCGN, GNFT, CABA, FENC, ARYD, IPHA, and OPT
Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Century Therapeutics (IPSC), Jasper Therapeutics (JSPR), Molecular Partners (MOLN), Ocugen (OCGN), Genfit (GNFT), Cabaletta Bio (CABA), Fennec Pharmaceuticals (FENC), ARYA Sciences Acquisition Corp IV (ARYD), Innate Pharma (IPHA), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.
Gritstone bio vs.
Century Therapeutics (NASDAQ:IPSC) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
Century Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Gritstone bio has higher revenue and earnings than Century Therapeutics. Gritstone bio is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
35.8% of Century Therapeutics shares are owned by institutional investors. Comparatively, 48.1% of Gritstone bio shares are owned by institutional investors. 10.3% of Century Therapeutics shares are owned by insiders. Comparatively, 4.5% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Gritstone bio has a net margin of -600.09% compared to Century Therapeutics' net margin of -2,518.41%. Century Therapeutics' return on equity of -38.02% beat Gritstone bio's return on equity.
In the previous week, Century Therapeutics had 22 more articles in the media than Gritstone bio. MarketBeat recorded 27 mentions for Century Therapeutics and 5 mentions for Gritstone bio. Gritstone bio's average media sentiment score of 0.64 beat Century Therapeutics' score of 0.30 indicating that Gritstone bio is being referred to more favorably in the news media.
Century Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 433.71%. Gritstone bio has a consensus price target of $5.00, suggesting a potential upside of 100.00%. Given Century Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than Gritstone bio.
Gritstone bio received 113 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 68.56% of users gave Gritstone bio an outperform vote while only 57.14% of users gave Century Therapeutics an outperform vote.
Summary
Century Therapeutics beats Gritstone bio on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gritstone bio Competitors List
